Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 217-126-9 | CAS number: 1746-23-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- In-life phase: 07 April 2018 to 27 April 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 019
- Report date:
- 2018
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- GLP compliance:
- yes (incl. QA statement)
Test material
- Reference substance name:
- p-tert-butylstyrene
- EC Number:
- 217-126-9
- EC Name:
- p-tert-butylstyrene
- Cas Number:
- 1746-23-2
- Molecular formula:
- C12H16
- IUPAC Name:
- p-tert-butylstyrene
- Test material form:
- liquid: volatile
1
- Specific details on test material used for the study:
- Lot/Batch no.: 111617TBSSV-2
Purity: 96.4%
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on test animals or test system and environmental conditions:
- Age at first dose: 8-9 weeks
Weight range at mating (GD 0): 180-210 g
Weight range at first dose: 197.9-245.9 g
Animals were acclimated to laboratory conditions for a minimum of 1 day prior to the first dose and released from acclimation by a staff veterinarian. During that time, animals were identified by a temporary number that was recorded on each cage label.
Animals were housed in one room in polycarbonate cages suspended on stainless steel racks. Each cage was affixed with a cage card containing pertinent animal and study information. Animals were individually housed.
Temperature: 20 to 26°C
Humidity: 30 to 70%
Light/Dark cycle:12-hour light/12-hour dark
Air changes: Minimum of 10 air changes per hour
Feed: Certified Global Teklad Laboratory Diet 2018 (pellets) was provided ad libitum.
Water: Filtered water was provided ad libitum via an automatic watering system supplemented with water bottles as needed.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- peanut oil
- Details on exposure:
- The formulations were placed at room temperature prior to dosing. The animals were dosed daily on GD 5 to 20 (day of confirmation of mating = GD 0) via oral gavage at a volume of 2.0 mL/kg. Dose volumes were based on the most recent body weights.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Stability analysis of the dose formulations was performed as part of the method validation. Test substance formulations were solutions; therefore, homogeneity sampling and analysis was not required. Samples from dose formulations prepared for week 1 and last week were analyzed for concentration verification using a validated method.
- Details on mating procedure:
- Time-mated female Sprague Dawley rats were received by the test facility.
- Duration of treatment / exposure:
- The animals were dosed daily on GD 5 to 20 (day of confirmation of mating = GD 0).
- Frequency of treatment:
- Daily once
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Dose / conc.:
- 20 mg/kg bw/day (nominal)
- Dose / conc.:
- 60 mg/kg bw/day (nominal)
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 25 per dose group
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Animals were initially accepted into the randomization pool based upon GD 0 body weights provided by the vendor. The suitability of the randomized animals was confirmed by physical examinations upon arrival. They were assigned to study groups using computer-generated random numbers such that the mean body weight for each group was not statistically different (p ≤ 0.05) from the control mean. Following randomization each study animal was assigned a unique number and identified by an ear tag.
Examinations
- Maternal examinations:
- Cageside observations included observation for mortality, morbundity, general health, and signs of toxicity (only abnormal findings were recorded during the cageside observations). Physical examinations included evaluation of skin and fur characteristics, eye and mucous membranes, respiratory, circulatory, autonomic, and central nervous systems, and somatomotor and behavior patterns.
- Ovaries and uterine content:
- The abdominal cavity was opened, the uterus was excised, and the gravid uterine weight was recorded. Beginning at the distal end of the left uterine horn, the location of viable and nonviable fetuses, early and late resorptions for each uterine horn, and the number of total implantations were recorded. The number of corpora lutea on each ovary was also recorded. The embryonic membrane of each fetus was gently removed. The fetuses were removed from the uterus and the placentae were grossly examined. Each implant was categorized as viable, nonviable, late resorption, or early resorption. Uteri from females that appeared to be nongravid were opened and placed in 10% ammonium sulfide solution for detection of implantation sites. The foci, if detected, were considered early resorptions, and data from these females were not included in mean calculations and statistics. If no foci were seen, the female was considered to be non-pregnant and data from these females were also not included in mean calculations or statistics.
- Fetal examinations:
- All live fetuses were individually weighed, identified, sexed, and examined for external malformations and variations. Following completion of the external examination of all fetuses in the litter, each fetus was euthanized. Approximately one-half of the fetuses in each litter were examined viscerally by fresh tissue dissection. The sex of the fetus was recorded. The heads were examined by Wilson’s sectioning. The remaining fetuses had the internal sex recorded and then were eviscerated, preserved, stained with Alizarin Red S and Alcian Blue, and examined for skeletal abnormalities. Fetal findings were classified as malformations or developmental variations. All fetal malformations were photographed, digitally saved and archived with the study file.
Intact fetuses from dams that died within 24 h of scheduled euthanasia were evaluated to the extent possible for external malformations and variations and sexed. All other intact fetuses from females not surviving to scheduled euthanasia were examined externally to the fullest possible extent and discarded. - Statistics:
- See under "any other information on materials and methods incl. tables".
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- effects observed, treatment-related
- Dermal irritation (if dermal study):
- no effects observed
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Significant reduction in gravid uetrine weight which corresponded to reduced body weights.
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- not specified
Maternal developmental toxicity
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- no effects observed
- Changes in number of pregnant:
- no effects observed
- Other effects:
- not specified
Effect levels (maternal animals)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 20 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- clinical signs
- mortality
Maternal abnormalities
- Key result
- Abnormalities:
- effects observed, treatment-related
- Localisation:
- other: general systemic toxicity
Results (fetuses)
- Fetal body weight changes:
- effects observed, treatment-related
- Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Changes in postnatal survival:
- no effects observed
- External malformations:
- no effects observed
- Skeletal malformations:
- no effects observed
- Visceral malformations:
- no effects observed
- Other effects:
- not specified
Effect levels (fetuses)
- Key result
- Dose descriptor:
- LOAEL
- Effect level:
- 20 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- fetal/pup body weight changes
Fetal abnormalities
- Key result
- Abnormalities:
- effects observed, treatment-related
- Localisation:
- other: Reduced body weight and reduction in body weight gain
- Description (incidence and severity):
- observed at all dose levels
Overall developmental toxicity
- Key result
- Developmental effects observed:
- yes
- Lowest effective dose / conc.:
- 20 mg/kg bw/day (nominal)
- Treatment related:
- yes
- Relation to maternal toxicity:
- developmental effects in the absence of maternal toxicity effects
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Under the study conditions, the NOAEL for maternal systemic toxicity was determined to be 20 mg/kg bw/day. No NOAEL for fetal developmental effects could be determined due to effects at all doses and therefore, the LOAEL for fetal developmental toxicity was considered to be 20 mg/kg bw/day.
- Executive summary:
A prenatal developmental toxicity study was conducted in Sprague Dawley rats according to OECD Guideline 414, in compliance with GLP. The test substance was administered to groups of 25 time-mated Sprague Dawley female rats at 0, 20, 60 or 100 mg/kg bw/day through oral gavage from Gestation Day 5 to 20 (GD 5 to GD 20). Dams were subjected to a full gross necropsy and uterine and fetal examinations on GD 21. Parameters evaluated during the study included mortality, physical examinations, cageside observations, body weights, body weight changes, food consumption, gross pathology examinations, uterine data, and fetal examination data (external, visceral, skeletal, and head exams). Dose concentration analysis of samples from formulations prepared for Week 1 and the last week of dosing confirmed that the test substance was properly formulated. Administration of the test substance resulted in maternal mortality at 100 mg/kg bw/day due to body weight loss, decreased food consumption and associated clinical signs of rough haircoat and thin appearance. At 60 mg/kg bw/day, the adverse effects included reduced food consumption and body weight in the dams. There were no effects on pregnancy and uterine parameters including the number of live fetuses as a percentage of post-implantation sites. There was an increase in the incidence of fetal defects (malformations and variations) in all the treated groups. These skeletal variations included incomplete ossification and unossification of the sternebrae and cervical and thoracic centrum and were attributed to the increase in the incidence of unossified or incomplete ossification. These skeletal variations were considered secondary to the reduction in fetal body weight and associated with delayed ossification. Due to their reversible nature, these variations were considered non-adverse, as the offspring would continue to grow and the ossification process would continue until complete with no expected structural alterations. Under the study conditions, the NOAEL for maternal systemic toxicity was determined to be 20 mg/kg bw/day. No NOAEL for fetal developmental effects could be determined due to effects at all doses and therefore, the LOAEL for fetal developmental toxicity was considered to be 20 mg/kg bw/day (Murphy, 2019c).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.